Top News
ALK TKI Therapy Yields Poor Outcomes in Real-World NSCLC Patients
“Good-Risk” Group of Patients With Myeloma Saw Better Outcomes
High Molecular Response With Lenalidomide, Rituximab in Untreated Follicular Lymphoma
Safety, Efficacy of Addition of Daratumumab to Treatment in Relapsed or Refractory Multiple Myeloma
Addition of Pazopanib to Neoadjuvant Chemo Found Highly Active in Adult, Pediatric Sarcoma
ACS Issues Updated Guideline for Cervical Cancer Screening
Identifying Risk Factors for Invasive Fungal Infection in Ibrutinib-Treated CLL Patients
Longitudinal MicroRNAs Lacked Predictive Value in Ovarian Cancer
Sorafenib Maintenance Therapy After Allo-HSCT Improves Outcomes in FLT3-ITD–Positive AML
Pregnancy After BRCA-Mutated Breast Cancer Deemed Safe
Zenocutuzumab Gets Orphan Drug Designation for Pancreatic Cancer
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
Children With Cancer Not Experiencing as Severe COVID-19 as Initially Feared
Studies suggest that the majority of pediatric patients with cancer and COVID-19 experience mild disease — rather than severe disease — as a result of infection with the novel virus. -
Upfront Radiation May Be a Cost-Effective Strategy in Oligorecurrent Hormone-Sensitive Prostate Cancer
Upfront metastasis-directed therapy may be a viable treatment approach in patients with oligorecurrent disease, particularly those who wish to defer systemic therapy. -
New Class of Drug Appears to Extend Survival in Patients With Triple-Refractory Multiple Myeloma
Oncopeptides will seek accelerated approval from the FDA after melflufen demonstrates a manageable safety profile. -
Study Points to a Rise in Renal Carcinomas in Children
The increase is thought to be related to environmental factors. -
Use of ICIs for Advanced Melanoma in Taiwanese Patients
It was determined that ICIs were less efficacious in Taiwanese patients with melanoma. -
Researchers Reveal Racial Disparities in Access to Remdesivir for Patients With Cancer and COVID-19
Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19. -
A Combination of Potential Biomarkers May Help Predict Response to Immunotherapy in mRCC
Combining 2 predictors yielded better results than just using 1.
More Features
The Vital Role Genetic Testing Plays in Bladder Cancer Treatments
Recent research suggests cancer patients who have undergone genetic testing for inherited or acquired mutations were more likely to have prolonged overall survival than patients who did not,
Examining Progress and Future Directions in Follicular Lymphoma Treatment
Researchers examine how far follicular lymphoma treatment has come, what limitations still remain, and where the management of the disease is headed.
Prostate Cancer Immunotherapy Alone Is Not Enough
So far, prostate cancer immunotherapy has shown only modest benefits. To greatly improve outcomes, immunotherapy will need to be combined with other treatments, according to the authors of a recent review.
Researchers Hope to Harness AI to Understand, Predict Response to ICIs
Regardless of the efficacy of immune checkpoint inhibition in some settings, many cancers will not respond to treatment with them.
AEs From Ibrutinib in Real-World CLL: More Research Needed
Some tyrosine kinase inhibitors may cause a hyperinflammatory response.
-
Loading...
-
Loading...
